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Abstract: 
Treatment of chronic total occlusion (CTOs) should be considered if associated with 
symptoms or evidence of myocardial viability. Historically, treatments of CTOs in the contest 
of multivessel (MVD), left main stem (LMS), and/or left anterior descending (LAD) disease 
have been via coronary artery bypass grafting (CABG-CTOs). Yet, over recent years, a vast 
amount of literature is showing that in North America, Europe, and Japan CABG-CTOs are 
being treated percutaneously (CTO-PCI). The evidence-based medicine SYNTAX trial 
confirms the superiority of CABG at 1 and 5 years in MACCE events across all the patient 
categories, including large subsets of CTO patients. This superiority appears disproportionate 
for patients with high SYNTAX score or with CTOs. This is in keeping with a large body of 
evidence favouring the use of CABG-CTOs for these anatomical categories.  
The use of CTO-PCI for surgical anatomical categories is based on questionable evidence 
derived from “comfortable” comparisons between successful vs. failed CTO-PCI procedures, 
with no controls. These comparisons suggest, in fact, that CTO-PCI might be causing 
significant harm to patients suffering procedural failures. This safety aspect seems to be 
grossly misrepresented  in the literature, against a disproportionate emphasis on CTO-PCI 
efficacy often softly defined as “on table successful recanalization”, which is neither 
synonymous of improved myocardial perfusion/function nor evidence of late patency.  This is 
a word of caution on the indication for PCI-CTO in “surgical” patients and on the need to 
address the safety and the efficacy of CTO-PCI via rigorous research. 
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1. Introduction 
Coronary artery chronic total occlusions (CTOs) are an exacerbation of stable coronary artery 
disease (CAD) with advanced calcification. CTOs are defined as 100% coronary occlusions 
with thrombolysis in myocardial infarction (TIMI) 0 flow persisting for > 3 months 1. 
National database registries and large single centre series suggest that in patients with CAD 
the overall incidence of CTOs may vary from 16-19% in Japan2 to 29-33% in North 
America3, suggesting that this is a prevalent problem globally. Treatment of CTOs should be 
considered if associated with symptoms and/or viable/ischemic myocardial territories. 
Historically, treatments have been via coronary artery bypass grafting (CABG) or medical 
therapy 3-9. 
The use of percutaneous coronary intervention (PCI) to treat CTOs (CTO-PCI) against 
established practice is controversial10. This controversy is facilitated by poor evidence 
available and by lack of clarity in the European and American guidelines for 
revascularization including those for patients with stable CAD11-15. However, the lack of 
robust evidence and unclear guidelines can lead to ill-defined clinical indications determining 
serious geographical discrepancies in CTO-PCI medical practice.  In a recent report from 
Japan more than 61% of patients diagnosed with CTOs (19% of all CAD patients) were 
treated with CTO-PCI2.  This is a significant increase compared with a previous  report from  
North America in which only 6-9% of all CTOs (29-33% of all CAD cases) were treated with 
CTO-PCI (range 1% to 16% by geographical area/centre)3. The report by Yamamoto and co-
workers2 suggests a widespread use of CTO-PCI in patients with multivessel CAD. This is 
likely to be at the expense of more established treatments such as CABG. The difference in 
CTO-PCI practice observed between Japan and North America is not easily explained.  
Contributing factors may be differences in study period, unclear guidelines, misrepresentation 
of safety/efficacy evidence supporting the use of CTO-PCI, neglect of the evidence 
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supporting more established treatments, gatekeeper effect, as well as the lack of policies by 
health authorities.  
In this article we provide evidence to support the view that CABG surgery remains the gold 
standard for the treatment of CTOs in patients with isolated left main stem (LMS), left 
anterior descending (LAD) or with CTOs in the context of multi-vessel CAD. In addition we 
explore safety and efficacy concerns behind the widespread use of CTO-PCI. 
 
2. Baseline determinants of health outcome and decision making in patients with CTOs 
For patients with CTO the decision making process should be based on a meticulous 
evaluation of the coronary anatomy, the complexity of each patient risk profile, the support of 
the Heart Team, the reference to evidence-based medicine, and on a fully informed patient. 
Clinical and cardiac specific variability of patients with CTOs 
Patients with CTOs may have a complex risk profile with higher incidence of   diabetes 
mellitus, multi-vessel disease (MVD), LMS coronary disease, diffuse coronary and peripheral 
vascular disease, and aggressive calcification of their coronary vessels resulting in higher 
SYNTAX scores16, 17. Additional variability may derive from differences in cardiac risk 
factors such as presence of single or multi-vessel CAD, extensive left ventricular (LV) 
scarring and/or residual viability/hibernation in the CTO territory, which may reflect on LV 
function18, 19, ischemic burden (if any), and symptoms status (asymptomatic or chronic stable 
angina)20, 21. 
Coronary anatomical variability of CTOs 
The anatomical assessment of CAD is based on coronary angiography. However, with CTOs 
often the affected coronary artery is poorly seen via retrograde filling from collaterals. This 
may trigger a degree of uncertainty of its quality and size. Contrast computer tomography 
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may however provide information on the severity and distribution of coronary calcification 
and length of CTOs. Intravascular ultrasound or optical coherence tomography have no 
diagnostic benefits although they may be helpful during CTO-PCI.  The Canadian 
Multicentre CTO Registry showed that only in <10% of cases an isolated CTO lesion is 
outside the LMS, LAD or MVD CAD context. In particular, the Registry showed that 47% of 
solitary CTOs occur in the right coronary artery (RCA), 20% in the LAD and 16% in the left 
circumflex (CX), that CTOs in more than one coronary artery were noted in 17% of the cases, 
and that MVD was present in 76% of patients with CTOs, of whom 7% were afflicted by 
LMS disease22. Similar distributions of CTOs have been reported by other investigators2, 4, 22-
24.  
The anatomic location of CTOs within each coronary artery can be either at the proximal/mid 
segment or at the mid/distal segment. This may have treatment implications as PCI 
procedures are in the majority of cases  not suitable for distal coronary segments (hence not 
able to treat distal CTOs) while CABG procedures are generally performed in distal coronary 
segments, hence able to treat both proximal and distal CTOs (Figure 1). This is supported by 
the inclusion criteria of both the DECISION-CTO (Drug-Eluting Stent Implantation vs 
Optimal Medical Treatment in Patients with Chronic Total Occlusion) and the EuroCTO 
(European Study on the utilization of Revascularisation vs Optimal Medical Treatment for 
the Treatment of Chronic Total Coronary Occlusion) trials (clinicaltrials.gov identifiers 
NCT01078051 and NCT01760083 respectively) which include in their angiographic 
inclusion criteria a target coronary size of “2.5mm or ≥2.5mm”, hence clearly excluding 
patients with distal CTOs. Similarly, the EXPERT-CTO (Evaluation of the XIENCE 
PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, 
Performance, and Technique in Chronic Total Occlusions) pilot trial (clinicaltrials.gov 
identifiers NCT01435031) included in its angiographic inclusion criteria “Segment not 
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located in an excessively distal location”. The inclusion/exclusion criteria of these studies 
suggests that CTO-PCI procedures target CTOs in proximal-mid coronary segments, while 
generally excluding those with distal coronary CTOs. 
In addition, the length of CTOs may vary from few millimetres to > 40mm with long CTOs 
often associated with scarred/infarcted myocardium and associated with worse health 
outcome23. Long CTOs may at times affect coronary bifurcations of sizable branches and this 
may have implications on the treatment to select to ensure a complete and effective 
revascularisation of both branches.   
Pathophysiology of stable CAD and CTOs 
Severe atherosclerotic CAD is associated with endothelial dysfunction affecting the ability to 
increase blood flow in response to changing metabolic demands, hence leading to myocardial 
ischaemia25, 26. Spontaneous rupture of severely stenotic plaques and thrombotic 
complications often lead to MI and sudden death27, 28, although they may also go clinically 
undetected due to healing of the ruptured plaque29, 30. However, MI and acute coronary 
syndromes more often occurs by rupture/thrombosis of mild/moderate plaques, suggesting 
that “in plaque” events play a role in sudden death and fatal MI29, 31. Hence, methods of 
coronary revascularisation should minimise the chances of additional iatrogenic “in plaque” 
or distal events. Given that CTO-PCIs are “in-plaque” procedures determining iatrogenic 
plaque ruptures during prolonged wiring/ballooning/stenting they can lead to acute 
thrombosis and/or distal coronary microembolisation.  Hence these procedures pose potential 
safety concerns which need proper investigating.   
 
3. Evidence supporting the use of CABG for the treatment of CTOs in patients with 
LMS, LAD, and MVD 
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Impact of CABG on revascularisation rates, health outcome and graft patency rates 
Historically, the treatment of CTOs has been assigned to CABG or medical therapy5-9. The 
superiority of CABG surgery vs PCI-stenting in patients with MVD, LMS or impaired LV 
function is confirmed by the SYNTAX trial16, 17. This evidence-based medicine trial 
illustrates that treating CTOs with CABG is associated with excellent early and long-term 
health outcome. Hence, alternative methods of CTO revascularisation targeting this type of 
patients should be compared versus CABG surgery as the established standard. Data from the 
UK National Data Registry32 shows that for all patients with stable and elective CAD the 
utilisation of a left internal mammary artery (LIMA)-LAD graft is at 95%. This is associated 
with a 30-day mortality of only 1.0%, as well as a postoperative incidence of stroke and 
reopening for bleeding of 0.9% and 2.9%, respectively. Only 0.2% of patients are re-operated 
for revision of grafts problems. Of note, the observed mortality has decreased markedly over 
time and it is consistently lower than the mortality predicted by logistic EuroSCORE32.  In 
keeping with the outcome of the UK Registry a study of 21,640 patients from an USA 
Registry undergoing CABG with on or off pump techniques reported an in-hospital mortality 
rate of 2.3%, 2.1% of reoperation for bleeding, 1.5% stroke, and 0.5% perioperative MI33. 
This outcome is confirmed by a very large recent study with more than 1.5 million CABG 
patients also from USA34.  
In the SYNTAX trial the superiority of CABG vs PCI was obvious at 12-month for the 
primary outcome major adverse cardiac or cerebrovascular events (MACCE) 16. The 
difference become striking at the final 5-year evaluation (MACCE 26.9% vs. 37.9%; cardiac 
death 5.3% vs. 9.0%, myocardial infarction 3.8% vs. 9.7% and need for repeat 
revascularisation 13.7% vs. 25.9%) 17. This trial showed that patients with intermediate or 
high SYNTAX score (many with CTOs) disproportionately benefited from CABG16, 17.  The 
5-year rate of MACCE events of the CABG arm of the SYNTAX trial was low and 
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comparable to the rate of MACCE events observed in the parallel SYNTAX CABG Registry 
(26.9% vs 23.2% respectively). This is a remarkable finding as the CABG Registry cohort 
(n=644) included as many as 56.4% of patients with CTOs vs. 22.2% of the CABG arm of 
the trial. Yet, the rates of completeness of revascularisation, was 74.7% vs. 63.2% 
respectively. This finding also suggests that a rate of CTOs as high as 56.4% in CABG 
surgery practice does not affect long-term health outcome. This important finding derived 
from an evidence-based medicine trial establishes a comparative standard for CTO-PCI 
practice to match. The SYNTAX PCI Registry cohort (n=192) included less patients with 
CTOs compared to the CABG Registry (36.5% vs. 56.4% respectively) as reflected in a 
lower SYNTAX score (31.6±12.3 vs. 37.8±13.3). Yet, the completeness of revascularisation 
in this group was much lower at 36.5% vs. 74.7% of the CABG registry cohort. Hence, 
CABG surgery can achieve very high rate of completeness of revascularisations, regardless 
of the incidence of CTO lesions and of levels of SYNTAX score. This is not the case for PCI. 
The rate of MACCE events at 5-year between the CABG and PCI registries, both with higher 
incidence of CTOs compared to the trial cohorts, favoured disproportionately CABG (23.2% 
vs. 49.2%, respectively) 35.  
 
Other studies focusing on CTOs patients also demonstrate excellent outcomes associated with 
the use of CABG. Data are available comparing the two subsets of CTO patients entered in 
the SYNTAX trial35. The trial included a total of 543 CTO patients (CABG n-266; PCI 
n=277) with similar coronary distribution and SYNTAX score between these two cohorts. 
The overall success rate for treatment of CTOs (including cases not attempted) was 68.1% vs. 
49.4%, CABG vs PCI respectively. In the CABG subset 97.8% CTOs were treated with at 
least one arterial graft. In the PCI subset the procedure was staged in 20.3% of patients, with 
use of an average of 5.0±2.2 stents per patient (range 8-80mm of stents). In these sub-groups 
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health outcome at 12 months showed a significant difference in MACCE events at 12.2% vs. 
18.9% CABG vs. PCI respectively16.  
Banerjee et al. 23 reported a series of 605 consecutive patients undergoing CABG, of whom 
256 patients (42%) had CTOs. All LAD-CTOs (27.2% of all CTOs) were bypassed 
successfully (with LIMA grafts) vs. 92% of the circumflex (CX) and right coronary artery 
(RCA) arteries. Among patients with multiple CTOs (26.2%), 85.2% had all CTO territory 
bypassed. At 1-year there was no difference in the incidence of MACE events (8.0% vs. 7.8% 
CTO vs. non-CTO groups).  However, longer CTO length (>40 mm) was associated with 
higher mortality at one year. The need for repeat revascularization (including PCI) was higher 
in the non- CTO group, although no difference was observed in need for repeat CABG (5.0% 
vs. 5.1%, CTO vs. non-CTO groups, respectively). Freedom from cardiac death at 1-year was 
significantly lower in the CTO group (p < 0.048).  These findings are in keeping with the 
report by Fefer et al. 36 in a series of 405 consecutive CABG patients including 174 cases 
with a total of 221 CTOs, of which 86% were successfully bypassed (100% LAD-CTO 
bypassed successfully).  
Effectiveness of LIMA-LAD graft and long-term patency rates of CABG 
There is evidence in the literature that CTO-PCI is being used extensively in patients with 
CTO lesions of the LAD alone or in the context of MVD2.  This is surprising when 
considering that the patient benefits associated with the LIMA-LAD graft have been 
transformational with limited in-hospital risks, improved life expectancy benefits, and very 
high patency rates (92-95%) at 15-20 years37, 38. The benefits of the LIMA-LAD grafts 
questions the reasons for undertaking CTO-PCI of the LAD in symptomatic patients. 
Confirmatory studies demonstrate improved 10-year actuarial survival rates associated with 
the use the LIMA conduit as opposed to saphenous vein grafts (SVG) only, making the 
pedicled LIMA-LAD graft the dogma of modern coronary surgery. In keeping with these 
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findings, other confirmatory studies suggest that not using a LIMA-LAD graft is associated 
with an increased risks of late MI, recurrence of angina, and need for repeat revascularisation 
37, 38.   
The excellent long-term patency rate of the LIMA-LAD graft is confirmed also for patients 
with CTO-LAD (Figure 2A and 2C). Holzhey et al.39 reported a series of 1800 patients 
undergoing single LIMA-LAD grafts via left mini-thoracotomy on the beating heart, of 
whom 420 patients had LAD-CTOs. In this series 99.8% of LAD-CTOs were grafted 
successfully. Five-year survival rates were excellent at 90.5% and 90.4% for the CTO vs non-
CTO groups respectively (p = 0.91). In addition, 5-years freedom from MACCE events was 
83.2% vs. 85.5%, CTO vs non-CTO groups, respectively (p=0.64), while CTOs were not 
found to be predictors of late MACCE events. Accordingly, Di Giammarco and colleagues40 
reported 143 patients with isolated LAD-CTO treated with LIMA-LAD grafts on the beating 
heart via left anterior small thoracotomy. Thirty-day mortality was 0.7%, with no occurrence 
of MI, cerebrovascular accident, or need for repeat revascularization. One-year survival was 
98.6%, with freedom from cardiac death at 99.3%, 100% freedom from MI, 99.3% freedom 
from any form of repeat revascularisation, and 97.9% freedom from MACE events. In 
addition, eight-year survival was 94.9%, freedom from cardiac death was 96.3%, with 99.2% 
freedom from MI, 94.4% freedom from any repeat revascularisation, and 92.8% freedom 
from MACE events. At 6-months after surgery 56% of patients had undergone control 
angiography with patency rates of 98.2%. Finally, the PRAGUE-4 trial in 400 patients 
undergoing off-pump coronary surgery showed a patency rate of CTO-LAD grafts of 100% 
at 1 year41.  
 CABG revascularisation of CTOs with SVG grafts 
One of the arguments against surgical intervention for single vessel CAD other than LAD 
disease is the long-term patency rates of saphenous vein grafts (SVGs). Historical data on 
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SVG grafts long term patency rate suggest that approximately 50% of these grafts become 
occluded within 10-years37, 38. This also means that the remaining 50% SVG grafts remain 
patent beyond the 10-year cut off (Figure 2B).  However, more recent reports suggest SVGs 
patency rates of as high as > 80% at long-term follow up in some centres possibly as result of 
improved management of postoperative anti-platelet function, refinement of surgical 
approaches with utilisation of less invasive SVG harvesting techniques42, and the a better 
understanding of the mechanisms involved in developing vein grafts inflammation and 
intimal hyperplasia43-45. For example, the 7-year patency rates of the BHACAS trials assessed 
with multi-slice CT scans showed an overall 89% patency rates in both the on-pump and off-
pump groups despite utilisation of SVGs for approximately 75% of grafts46. 
Efficacy of CABG for CTOs affecting coronary vessels other than the LAD 
For the rare condition of LMS-CTO (0.04-0.4% of all CTOs) small surgical series have been 
reported with excellent revascularisation rates and late outcome with successful use of 
LIMA-LAD grafts47-49. Successful revascularisation rates are reported at 80-90% for CTOs of 
LCX, with >80% of patients having all multiple CTOs treated successfully and 
concomitantly23, 36. Fefer et al. 36 showed that presence of CTOs was not associated with 
increased mortality by multivariate analysis. The study also suggested that failure to 
revascularize a non-LAD CTO was not associated with adverse long-term outcome. 
CTOs requiring endarterectomy during CABG 
Occasionally, surgeons have had to deal with complex, distal and long CTO lesions by 
performing more invasive procedures such as endarterectomy.  Gill et al.50  reported a small 
series of 74 patients undergoing LIMA-LAD, in whom 25 patients received endarterectomy 
to remove the CTO lesion prior to positioning the LIMA graft. This approach was associated 
with high inotropic requirement in 25% of the patients and a 6.7% incidence of postoperative 
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MI. This study nonetheless is unfortunately too small for any meaningful considerations. 
However, it is wort noting that the rates of these postoperative complications were unusually 
high by routine CABG standards, whilst supporting the concept that increased coronary 
invasiveness is associated with worse cardiac specific outcome. 
 
4. Evidence supporting the use of PCI-stenting for the treatment of CTOs in patients 
with LMS, LAD, and MVD 
The use of CTO-PCI is wide spreading due to advances in PCI technologies including 
“parallel” and “seesaw” wire techniques, balloon anchoring, sub-intimal tracking and re-entry 
(STAR), retrograde approach, contralateral injection, and intravascular ultrasound guidance51. 
Claims of PCI efficacy for CTO-PCIs are mostly based on observational studies comparing 
successful vs failed CTO-PCI recanalizations with misrepresentation of the iatrogenic effects 
determined by CTO-PCI undertaking in the cohorts suffering failed procedures.  
Comparing successful vs failed CTO-PCIs: a fair trade-off?  
Comparing successful versus failed PCI-stent for CTOs does not provide evidence of the 
efficacy of CTO-PCI versus other forms of revascularisation. Rather, this approach may 
allow ascertaining potential safety concerns based on the severity and rates of serious 
complications observed in the failed CTO-PCI groups. We simply do not know what would 
have happened to the patients suffering a failed CTO-PCI, had they been offered instead 
more established treatments like medical therapy or CABG. Surprisingly, despite the lack of 
comparisons versus real control interventions, the outcome of the successful CTO-PCI 
procedures is being wrongly marketed as evidence of efficacy. Jones et al.52 reported 
retrospectively the outcome of 6996 patients treated with PCI-stent, of whom 836 (11.9%) 
had CTOs. The CTO-PCI success rate was suboptimal at 69.6%, with failed CTO-PCIs in 
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64/232 (28%) LAD-CTOs, 35/112 (31%) CX-CTOs, and 106/298 (35%) RCA-CTOs. These 
failures triggered a wide range of complications including coronary dissection which was 
much higher in the failed cases (20.5% vs. 4.9%; p < 0.0001), with 3.1% requiring urgent 
CABG. Multivariate analysis demonstrated that procedural failure was independently 
predictive of mortality (HR: 0.32, 95%CI: 0.18 to 0.58). Fang et al. 53 in a retrospective study 
in 621 CTO-PCI patients compared the outcome of PCI-stent in 551 LAD-CTOs vs. 70 ostial 
LAD CTOs. Ostial LAD CTO-PCIs were more complex and associated with prolonged 
operative and fluoroscopic time as well as increased use of contrast volumes. The European 
outcome of retrograde CTO-PCI procedures was reported by Galassi et al. 54 in 1,395 patients 
with 1,582 CTOs from 44 European centres. Despite the procedures were undertaken by 
skilled and experienced operators on table success rates were suboptimal at 70-75%. 
Distribution of CTO-PCI procedures included 70.4% RCAs, 7.8% CXs, 20.3% LADs, and 
1.5% for combined LMS and bypass grafts. The rate of technical failure was almost 20% for 
LAD-CTOs, accounting for about 4.5% of all failures. Procedural failures were independent 
predictors of MACCE events at long term follow up (HR: 2.48; 95% CI: 1.72 to 3.57; p < 
0.001). In addition, there were serious vascular complications in 16 patients, 30 cases of 
vessel thrombus or dissection, 4 emergency re-interventions, and 2 deaths in the failed CTO-
PCI group. Disappointedly, the clinical follow-up of about one-third of the patients was 
missing. For the remaining two thirds of patients followed up there were major discrepancies 
in type and completeness of variables collected, hence providing meaningless information on 
the late impact of CTO-PCI.  Patel et al. 55 performed a meta-analysis of 18,061 pooled CTO 
patients with 18,941 target CTOs. On table angiographic success was 77%. Early 
complication rates included MI at 2.5%, coronary perforation at 2.9%, tamponade at 0.3%, 
and contrast nephropathy at 3.8%. The use of CTO-PCI in the failed group was associated 
with higher rates of death (0.42% vs. 1.54%; P<.001). Moreover, very little data was 
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presented on late functional evaluations and angiographic patency rates.  Galassi et al. 56 
analysed data of 905 patients who were treated for 922 CTOs including 244 bifurcation CTOs 
(26.5%). The undertaking of bifurcation CTO-PCI was associated with larger use of contrast 
load, and higher number of stents, and a higher rate of coronary perforations compared to 
non-bifurcation procedures (4.9 vs. 1.7%; P<0.001), resulting in more tamponades (2.4 vs. 
0.2%; P<0.001). The EXPERT CTO study has recently reported 250 CTO-PCI patients from 
20 centres treated with a new generation of drug-eluted stent. Although the authors claims 
that the use of this stent may improve health outcome when compared with the results of 
previous studies it is fair to maintain that this was only a feasibility/pilot study with no 
control group and that the potential efficacy of the new stent will need to be ascertained in a 
proper head to head comparison in future trials57. 
 Late functional or angiographic evidence supporting the use of CTO-PCI 
Lack of functional or angiographic data is a consistent issue with CTO-PCI reports in the 
literature. However, anecdotal cases of early re-occlusions post CTO-PCI requiring surgical 
intervention are increasingly being discussed among surgeons (Figure 3A-D). Valenti and 
colleagues58, 59 reported two series of CTO-PCI procedures undertaken in 258 and in 1005 
consecutive patients. On-table recanalization success rates were 81% and 77% respectively. 
Six-nine month angiographic follow-up was available for 80% of all successful CTO-PCI 
procedures in both series. This showed an overall incidence of re-occlusion and/or restenosis 
>50% in 23.3% and 21% of patients respectively. This indicates an overall 6-9 month 
procedural failure (on-table failed recanalization plus late re-occlusion/restenosis) of 42.3% 
and 44% respectively. This angiographic data seems to raise a word of caution on the 
effectiveness of CTO-PCI and hopefully more robust evidence will soon be available in this 
area56, 57. 
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One recurrent claim in CTO-PCI retrospective reports is that the procedure leads to 
improvement in angina symptoms, LV function and survival20, 21. This is based on the 
assumption that CTO-PCI increases the blood supply to the ischemic CTO territory (often 
already supplied by collaterals). However, this assumption remains unsubstantiated. In the 
Occluded Artery Trial (OAT) 2166 stable CAD patients with total occlusion of the infarct-
related artery 3 to 28 days after MI were randomised to PCI stenting plus optimal medical 
therapy versus optimal medical therapy alone. This trial did not show any benefit associated 
with the use of PCI-stenting for the composite of death, myocardial re-infarction, or New 
York Heart Association (NYHA) class IV heart failure at 4-years (17.2% in the occluded 
artery group and 15.6% in the medical therapy group (HR 1.16; 95% CI, 0.92 to 1.45; 
P=0.20) while death rates were also similar (9.1% vs. 9.4%). Although the total occlusions of 
the OAT trial were not > 3 month chronic, hence probably easier to reopen, it’s worth noting 
that the use of PCI-stenting was not superior to medical therapy alone. In the FACTOR trial60 
125 patients with ischemic myocardium were treated with CTO-PCI. They completed the 
Seattle Angina Questionnaire at baseline and 1-month post procedure. At 1-month, in 
asymptomatic patients no benefit was associated to the use of CTO-PCI. This highlights the 
limitation of this approach in patients with ischemic myocardium but without angina, for 
whom a measure of prognostic outcome would be of greater value. In the COURAGE trial 
the impact on ischemic myocardium measured by nuclear imaging did not improve the mid-
term prognosis in the PCI-stent group6. Accordingly, Stergiopoulos et al.61  in a meta-analysis 
of trials in stable CAD patients with ischemic myocardium highlight that the use of PCI-stent 
did not improve the observed rates of death, MI, angina, and need for revascularisation 
compared to medical therapy. Similarly, others have suggested that CTO-PCI to LV 
hibernated/dysfunctional territories lead only to marginal, if any, effect even when using a 
sensitive imaging tool like MRI10. Nevertheless, the evidence of LV impairment triggered by 
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failed CTO-PCIs is of higher concern given the excessive rate of coronary dissection, 
perforations, and distal micro-embolizations reported62, 63.  
Another argument used is that successful CTO-PCIs improve prognosis compared to failed 
CTO-PCIs. This claim is surprising, given that CTO-PCI is the direct determinant of serious 
complications in the failed cohorts. One could simply argue the other way around that CTO-
PCIs in fact worsen the prognosis of patients undergoing failed procedure. The argument 
used by CTO-PCI promoters is based on pooled observations64 and is questionable as often 
retrospective pooled comparisons cannot take into account key differences in baseline 
characteristics between pooled groups due to lack or non-homogeneous data available. This is 
supported by the analysis of patients from the CREDO-Kyoto Registry (1192 successful 
CTO-PCIs vs. 332 failed CTO-PCIs), which in presence of homogenous baseline data 
available for the entire cohort suggests that at 3-year there is no difference in all-cause 
mortality between groups2. 
Invasiveness of CTO-PCI 
CTO-PCIs are very invasive procedures impacting both at systemic and at coronary/cardiac 
specific levels. They are associated with very long procedural and fluoroscopic times as well 
as increased use of contrast volumes and related incidence of renal failure52-54. Poor tolerance 
by sedated patients, complex risk profile, and prolonged procedural time are regarded as 
factors triggering the adoption of general anaesthesia instead of sedation65. The need for 
significant and prolonged platelet inhibition after CTO-PCI is not a trivial factor. Evidence 
suggests that patients with extensive coronary stents undergoing non-cardiac surgery early 
after stenting are at increased risk of MACE, with perioperative mortality rates as high as 
85% being reported due to different reasons including stent thrombosis as a result of stopping 
or changing antiplatelet regime66, 67. 
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One of the most concerning aspect of CTO-PCI is its excessive coronary invasiveness, which 
is unprecedented. This causes serious complications including coronary perforation, 
dissections, tamponade, acute thrombotic events, LV impairments, and peripheral vascular 
injuries. The occurrence of these complications is not surprising and probably should be 
expected  when considering the level of coronary invasiveness applied during  CTO-PCI, the 
off-label use of stents designed for non CTO lesions, the CTO-PCI related activation of 
patho-physiological mechanisms triggering acute thrombosis, chronic inflammation as well 
as repeated intra-coronary micro-embolization in the relevant viable myocardial territory 
which may impair LV function in line with the principles of established models of  chronic 
heart failure68. Patel et al. 55 in a meta-analysis of 18,061 pooled CTO patients with 18,941 
target CTOs reported a rate of coronary perforation of 3.65% vs. 10.70%, in successful vs 
failed CTO-PCIs (P<.001), with a related incidence of tamponade of 0% vs. 1.65% 
(P <.001). These numbers equal to hundreds of patients suffering poor health outcome caused 
by CTO-PCI procedures.  This is not an isolated observation. Mehran et al. 62 reported an 
analysis from the Multi-national CTO Registry in 1791 CTO patients. The rates of coronary 
dissection and perforation were of 4.3% and 1.7% and of 9.4% and 7.4% in successful vs. 
failed CTO-PCI, respectively.  Of note, the mortality rate of the failed CTO-PCI cohort was 
not reported. High rates of MI and need for emergency CABG were reported, but deaths after 
emergency CABG were omitted (to be ascribed by intention to treat to the failed CTO-PCI 
cohort). Excessive rates of serious complications have been reported by Japanese centres. 
Kimura et al. 69 in a series of 1014 CTOs in 943 patients compared the antegrade (n=733) vs 
retrograde (n=277) approaches. They reported extremely high rates of coronary dissection 
(14.7% vs. 10.1%), perforation (8.2% vs. 13%), and distal myocardial embolization (3.7% vs. 
1.4%) in the antegrade vs retrograde cohorts respectively.  
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The goal of CABG surgery is to position the anastomosis in a health coronary segment distal 
to the blockage (Figure 4A). Conversely, the goal of CTO-PCI stenting is to perform a 
variety of “in blockage procedures” including complex antegrade/retrograde wiring, high 
pressure ballooning, and multiple stenting (i.e. leaving behind foreign bodies triggering 
continuously in-plaque chronic thrombosis and inflammation) to achieve recanalization 
(Figure 4B). These technical differences between CABG and CTO-PCI are not trivial and 
might explain the rates of serious complications reported during  CTO-PCI stenting as well as 
the higher rates of early recurrence, cardiac specific complications, and worse late health 
outcome. Of note, when referred for emergency CABG failed CTO-PCIs present with rather 
dramatic findings (Figure 4C) often associated with deaths and/or major complications that 
are unlikely to be retained in the CTO-PCI cohorts of the observational studies available in 
the literature62, 63, 69. 
5. Conclusions 
Available evidence-based medicine derived from the COURAGE and OAT trials suggest that 
in patients with stable CAD or in those with occluded coronary arteries < 3 months the use of 
PCI-stenting is not superior to medical therapy alone. The ongoing DECISION-CTO and the 
EuroCTO trials once completed will help clarifying the impact of CTO-PCI versus medical 
therapy alone in these patients.   
The use of CTO-PCI is spreading quickly worldwide across CABG anatomical categories 
such as LMS, LAD, and MVD disease despite the establishment of the Heart Teams and 
despite strong evidence from large sub-analyses of CABG vs. PCI-stent trials and from large 
database registries supporting the superiority of CABG. The recent evidence-based medicine 
SYNTAX trial confirms the superiority of CABG at 1 and 5 years in MACCE events across 
all the patient categories including large subsets of CTO patients.  
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 The global promotion of CTO-PCI as an effective procedure across all CAD anatomical 
categories is of concern as it is based on questionable evidence derived only from 
“comfortable” comparisons between successful vs. failed CTO-PCI procedures with no 
controls. In fact, these “comfortable” comparisons suggest that CTO-PCI might be causing 
significant injury to patients suffering procedural failures. This key  safety concern seems to 
be grossly misrepresented  in the available CTO-PCI literature while  a disproportionate 
emphasis of efficacy seems to be based on soft findings such as on table successful 
recanalization, which is neither synonymous of improved myocardial perfusion/function nor 
evidence of late patency.  In this context, the undertaking of randomised trials comparing 
CABG vs. CTO-PCI in patients with LMS, LAD, and MVD does not seem to be justified on 
pure clinical grounds at this stage.   
On the ground of the available evidence we strongly suggests that all CTO patients should be 
carefully discussed at multidisciplinary Heart Team meetings including a balanced 
professional representation of surgeons and interventional cardiologists, bearing in mind that 
at this stage for CTO patients with LMS, LAD, and MVD disease CTO-PCI may have a role 
only for a certain type of sick population deemed to be not suitable for CABG.   
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Figure legends: 
 
Figure 1 
Schematic shows possible anatomical locations of CTO lesions. A: PCI coronary territory 
with lumen size 2.0-3.00mm; B: CABG coronary territory with lumen size 1.0-2.0mm.  
 
Figure 2 
Figure shows a case of multiple CTOs treated with CABG surgery in 2002 at our Institution; 
pictures are from a coronary angiogram taken in 2015. A: native left coronary system 
showing long CTOs involving the LAD and a Diagonal/Intermediate branches; B: patent 
SVG-Diagonal/Intermediate graft; C: patent LIMA-LAD graft. Unpublished data. 
 
Figure 3 
Figure shows a case of long CTO of Right Coronary Artery (RCA) treated with CTO-PCI at 
our Institution. A-D: Coronary angiogram taken in late 2013; A: long CTO is seen at the mid 
RCA segment (black arrows); B-C: wiring and ballooning of CTO; D: on table final result. E: 
Coronary angiogram taken early in 2015. Picture shows recurrence of CTO lesion at mid 
RCA segment (white arrows). Unpublished data. 
 
Figure 4 
Figure shows technical principles of coronary revascularisation and a CTO-PCI complication. 
A: CABG positions coronary anastomoses in a health coronary segments distal to the 
blockage; B: CTO-PCI involves invasive in-plaque procedures; C: Epicardial view of a 
coronary dissection in the proximal LAD (black arrows) requiring emergency CABG 
following failed CTO-PCI. 
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